Home > Journals > Minerva Surgery > Past Issues > Minerva Chirurgica 2017 October;72(5) > Minerva Chirurgica 2017 October;72(5):397-415

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Minerva Chirurgica 2017 October;72(5):397-415

DOI: 10.23736/S0026-4733.17.07409-0

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Positron emission tomography/computer tomography in gastrointestinal malignancies: current potential and challenges

Sofie TIND 1, Sys VESTERGAARD 1, Ziba A. FARAHANI 1, Søren HESS 1, 2, 3

1 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark; 2 Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; 3 Department of Radiology and Nuclear Medicine, Hospital Southwest Jutland, Esbjerg, Denmark


PDF


The use of 18F-Fluoro-D-deoxy-glucose -positron emission tomography/computed tomography (FDG-PET/CT) in gastrointestinal (GI)-malignancies may not be as straightforward as in many other cancers, but the potential is clearly there in select clinical settings. The challenges include the relative non-specificity of FDG, the variable degrees of physiologic FDG-uptake, and the heterogeneous FDG-uptake in different cell types within the GI-domain, which all together hamper the use in primary diagnostics. In general, the literature is older, heterogeneous, and based on stand-alone PET, which is now largely considered obsolete. There is emerging evidence for use of hybrid PET/CT, but the literature is still relatively sparse. The main indications are preoperative staging of distant metastases, not only in limited disease but also before curative treatment of limited metastatic disease. Controversies remain concerning liver metastases but improved technology boast well for the future role of FDG-PET/CT not least concerning equivocal findings on conventional imaging. In our opinion, an important upcoming indication is early response assessment, perhaps mostly in the neoadjuvant settings of upper GI-malignancies, but standardization of response assessment criteria is lacking before a more widespread implementation is feasible. Finally, there seems to be a significant role in recurrence detection, especially in CRC.


KEY WORDS: Fluorodeoxyglucose F18 - Positron emission tomography computed tomography - Radioisotopes - Gastrointestinal neoplasms - Stomach neoplasms - Pancreatic neoplasms

top of page